ImmuneInvestigational

Thymostimulin (TP-1)

Intramuscular injection, Subcutaneous injection

Overview

Thymostimulin is a polypeptide extract derived from bovine thymus tissue containing multiple biologically active thymic peptides. It acts on T-lymphocyte maturation and differentiation by mimicking thymic hormone activity.

Mechanism of Action

The therapeutic rationale centers on restoring or augmenting immune function in states of T-cell deficiency or immunosuppression..

Research Summary & Key Findings

Clinical investigations in the 1980s and 1990s explored thymostimulin in immunodeficiency states, chronic infections, and as an adjunct to cancer therapy, though results were inconsistent. Modern regulatory interest has diminished due to lack of standardized composition and robust efficacy data in controlled trials.

Clinical Status

Investigational

Thymostimulin (TP-1) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Intramuscular injectionSubcutaneous injection

Related Peptides in Immune

Find a Provider

Find a verified provider who offers Thymostimulin (TP-1) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Thymostimulin (TP-1).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.